Faculty & Staff Directory
- Associate Professor
MD, University of Padova (Italy), School of Medicine; MPH, George Mason University
The primary focus of my research is the delivery and implementation of precision medicine for cancer patients. My research model is based on a combination of translational studies and clinical trials with a focus on metastatic disease and on the tumor microenvironment. My lab works with in vitro models and patient-derived biological specimens. We use state-of-the-art technologies to explore spatial and dynamic interactions in cancer, and utilize this information to devise tailored, therapeutic solutions for our patients.
Baldelli E, et al. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas. Genes 2021;12(1402). https://www.mdpi.com/2073-4425/12/9/1402
Bryant KL, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019;25(4):628-640.
Pierbon et al., Enrichment of PI3K-AKT-mTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res 2017;23(16),4919– 4928.
Sereni MI et al., Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers. Br J Cancer 2017;117(4),494-502.
Pin E et al., A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using a laser capture microdissection and reverse phase protein microarray workflow. Mol Oncol 2016;10(10),1585-1594.
Baldelli E, et al. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget. 2016;6(32):32368-79.
Fulbright Scholar (2019), University of Udine (Italy), Department of Medical and Biological Sciences.